Blueprint Medicines (BPMC)
(Real Time Quote from BATS)
$57.83 USD
+1.04 (1.83%)
Updated Jun 2, 2023 11:48 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BPMC 57.83 +1.04(1.83%)
Will BPMC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMC
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for
Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound?
Other News for BPMC
Biotech Alert: Searches spiking for these stocks today
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
SVB Securities Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
Blueprint Medicines announces publication of results from PIONEER Trial